151
|
Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J, DePinho RA, Dannenberg JH. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 2010; 29:2586-97. [PMID: 20571512 DOI: 10.1038/emboj.2010.136] [Citation(s) in RCA: 186] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2010] [Accepted: 05/20/2010] [Indexed: 11/09/2022] Open
Abstract
Histone deacetylases (HDACs) counterbalance acetylation of lysine residues, a protein modification involved in numerous biological processes. Here, Hdac1 and Hdac2 conditional knock-out alleles were used to study the function of class I Hdac1 and Hdac2 in cell cycle progression and haematopoietic differentiation. Combined deletion of Hdac1 and Hdac2, or inactivation of their deacetylase activity in primary or oncogenic-transformed fibroblasts, results in a senescence-like G(1) cell cycle arrest, accompanied by up-regulation of the cyclin-dependent kinase inhibitor p21(Cip). Notably, concomitant genetic inactivation of p53 or p21(Cip) indicates that Hdac1 and Hdac2 regulate p53-p21(Cip)-independent pathways critical for maintaining cell cycle progression. In vivo, we show that Hdac1 and Hdac2 are not essential for liver homeostasis. In contrast, total levels of Hdac1 and Hdac2 in the haematopoietic system are critical for erythrocyte-megakaryocyte differentiation. Dual inactivation of Hdac1 and Hdac2 results in apoptosis of megakaryocytes and thrombocytopenia. Together, these data indicate that Hdac1 and Hdac2 have overlapping functions in cell cycle regulation and haematopoiesis. In addition, this work provides insights into mechanism-based toxicities observed in patients treated with HDAC inhibitors.
Collapse
Affiliation(s)
- Roel H Wilting
- Division of Molecular Genetics, Plesmanlaan 121, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
152
|
Spallotta F, Rosati J, Straino S, Nanni S, Grasselli A, Ambrosino V, Rotili D, Valente S, Farsetti A, Mai A, Capogrossi MC, Gaetano C, Illi B. Nitric oxide determines mesodermic differentiation of mouse embryonic stem cells by activating class IIa histone deacetylases: potential therapeutic implications in a mouse model of hindlimb ischemia. Stem Cells 2010; 28:431-42. [PMID: 20073046 DOI: 10.1002/stem.300] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
In human endothelial cells, nitric oxide (NO) results in class IIa histone deacetylases (HDACs) activation and marked histone deacetylation. It is unknown whether similar epigenetic events occur in embryonic stem cells (ESC) exposed to NO and how this treatment could influence ESC therapeutic potential during tissue regeneration.This study reports that the NO-dependent class IIa HDACs subcellular localization and activity decreases the global acetylation level of H3 histones in ESC and that this phenomenon is associated with the inhibition of Oct4, Nanog, and KLF4 expression. Further, a NO-induced formation of macromolecular complexes including HDAC3, 4, 7, and protein phosphatase 2A (PP2A) have been detected. These processes correlated with the expression of the mesodermal-specific protein brachyury (Bry) and the appearance of several vascular and skeletal muscle differentiation markers. These events were abolished by the class IIa-specific inhibitor MC1568 and by HDAC4 or HDAC7 short interfering RNA (siRNA). The ability of NO to induce mesodermic/cardiovascular gene expression prompted us to evaluate the regenerative potential of these cells in a mouse model of hindlimb ischemia. We found that NO-treated ESCs injected into the cardiac left ventricle selectively localized in the ischemic hindlimb and contributed to the regeneration of muscular and vascular structures. These findings establish a key role for NO and class IIa HDACs modulation in ESC mesodermal commitment and enhanced regenerative potential in vivo.
Collapse
Affiliation(s)
- Francesco Spallotta
- Laboratorio di Patologia Vascolare, Istituto Dermopatico dell' Immacolata - Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
153
|
Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS 2010; 1799:717-25. [PMID: 20594930 DOI: 10.1016/j.bbagrm.2010.05.008] [Citation(s) in RCA: 142] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2010] [Accepted: 05/28/2010] [Indexed: 01/29/2023]
Abstract
There are eleven zinc dependent histone deacetylases (HDAC) in humans which have histones and many non-histone substrates. The substrates of these enzymes include proteins that have a role in regulation of gene expression, cell proliferation, cell migration, cell death, immune pathways and angiogenesis. Inhibitors of HDACs (HDACi) have been developed which alter the structure and function of these proteins, causing molecular and cellular changes that induce transformed cell death. The HDACi are being developed as anti-cancer drugs and have therapeutic potential for many non-oncologic diseases.
Collapse
Affiliation(s)
- Paul A Marks
- Cell Biology and Genetics Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
| |
Collapse
|
154
|
Escobar J, Pereda J, Arduini A, Sandoval J, Sabater L, Aparisi L, López-Rodas G, Sastre J. Protein phosphatases and chromatin modifying complexes in the inflammatory cascade in acute pancreatitis. World J Gastrointest Pharmacol Ther 2010; 1:75-80. [PMID: 21577300 PMCID: PMC3091150 DOI: 10.4292/wjgpt.v1.i3.75] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2009] [Revised: 02/10/2010] [Accepted: 02/17/2010] [Indexed: 02/05/2023] Open
Abstract
Acute pancreatitis is an inflammation of the pancreas that may lead to systemic inflammatory response syndrome and death due to multiple organ failure. Acinar cells, together with leukocytes, trigger the inflammatory cascade in response to local damage of the pancreas. Amplification of the inflammatory cascade requires up-regulation of pro-inflammatory cytokines and this process is mediated not only by nuclear factor κB but also by chromatin modifying complexes and chromatin remodeling. Among the different families of histone acetyltransferases, the p300/CBP family seems to be particularly associated with the inflammatory process. cAMP activates gene expression via the cAMP-responsive element (CRE) and the transcription factor CRE-binding protein (CREB). CREB can be phosphorylated and activated by different kinases, such as protein kinase A and MAPK, and then it recruits the histone acetyltransferase co-activator CREB-binding protein (CBP) and its homologue p300. The recruitment of CBP/p300 and changes in the level of histone acetylation are required for transcription activation. Transcriptional repression is also a dynamic and essential mechanism of down-regulation of genes for resolution of inflammation, which seems to be mediated mainly by protein phosphatases (PP1, PP2A and MKP1) and histone deacetylases (HDACs). Class II HDACs are key transcriptional regulators whose activities are controlled via phosphorylation-dependent nucleo/cytoplasmic shuttling. PP2A is responsible for dephosphorylation of class II HDACs, triggering nuclear localization and repression of target genes, whereas phosphorylation triggers cytoplasmic localization leading to activation of target genes. The potential benefit from treatment with phosphodiesterase inhibitors and histone deacetylase inhibitors is discussed.
Collapse
Affiliation(s)
- Javier Escobar
- Javier Escobar, Javier Pereda, Alessandro Arduini, Juan Sastre, Department of Physiology, University of Valencia, 46100 Burjasot (Valencia), Spain
| | | | | | | | | | | | | | | |
Collapse
|
155
|
Adenuga D, Rahman I. Protein kinase CK2-mediated phosphorylation of HDAC2 regulates co-repressor formation, deacetylase activity and acetylation of HDAC2 by cigarette smoke and aldehydes. Arch Biochem Biophys 2010; 498:62-73. [PMID: 20388487 PMCID: PMC2874641 DOI: 10.1016/j.abb.2010.04.002] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2010] [Revised: 03/29/2010] [Accepted: 04/07/2010] [Indexed: 02/07/2023]
Abstract
Histone deacetylase 2 (HDAC2) mediates the repression of pro-inflammatory genes by deacetylating core histones, RelA/p65 and the glucocorticoid receptor. Reduced level of HDAC2 is associated with steroid resistant inflammation caused by cigarette smoke (CS)-derived oxidants and aldehydes. However, the molecular mechanisms regulating HDAC2 in response to CS and aldehydes is not known. Here, we report that CS extract, and aldehyde acrolein induced phosphorylation of HDAC2 which was abolished by mutations at serine sites S(394), S(411), S(422) and S(424). HDAC2 phosphorylation required direct interaction with serine-phosphorylated protein kinase CK2alpha and involved reduced HDAC2 deacetylase activity. Furthermore, HDAC2 phosphorylation was required for HDAC2 interaction with transcription factors, co-repressor complex formation, CBP recruitment, acetylation on lysine residues and modulates transrepression activity. Thus, phospho-acetylation of HDAC2 negatively regulates its deacetylase activity which has implications in steroid resistance in chronic inflammatory conditions.
Collapse
Affiliation(s)
- David Adenuga
- Department of Environmental Medicine, University of Rochester Medical Center, NY 14642, USA
| | | |
Collapse
|
156
|
Pelzel HR, Schlamp CL, Nickells RW. Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis. BMC Neurosci 2010; 11:62. [PMID: 20504333 PMCID: PMC2886060 DOI: 10.1186/1471-2202-11-62] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2009] [Accepted: 05/26/2010] [Indexed: 12/22/2022] Open
Abstract
Background Silencing of normal gene expression occurs early in the apoptosis of neurons, well before the cell is committed to the death pathway, and has been extensively characterized in injured retinal ganglion cells. The causative mechanism of this widespread change in gene expression is unknown. We investigated whether an epigenetic change in active chromatin, specifically histone H4 deacetylation, was an underlying mechanism of gene silencing in apoptotic retinal ganglion cells (RGCs) following an acute injury to the optic nerve. Results Histone deacetylase 3 (HDAC3) translocates to the nuclei of dying cells shortly after lesion of the optic nerve and is associated with an increase in nuclear HDAC activity and widespread histone deacetylation. H4 in promoters of representative genes was rapidly and indiscriminately deacetylated, regardless of the gene examined. As apoptosis progressed, H4 of silenced genes remained deacetylated, while H4 of newly activated genes regained, or even increased, its acetylated state. Inhibition of retinal HDAC activity with trichostatin A (TSA) was able to both preserve the expression of a representative RGC-specific gene and attenuate cell loss in response to optic nerve damage. Conclusions These data indicate that histone deacetylation plays a central role in transcriptional dysregulation in dying RGCs. The data also suggests that HDAC3, in particular, may feature heavily in apoptotic gene silencing.
Collapse
Affiliation(s)
- Heather R Pelzel
- Department of Biomolecular Chemistry, University of Wisconsin, 1300 University Ave, 6671 MSC, Madison, WI 53706, USA
| | | | | |
Collapse
|
157
|
Patzlaff JS, Terrenoire E, Turner BM, Earnshaw WC, Paulson JR. Acetylation of core histones in response to HDAC inhibitors is diminished in mitotic HeLa cells. Exp Cell Res 2010; 316:2123-35. [PMID: 20452346 DOI: 10.1016/j.yexcr.2010.05.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2009] [Revised: 04/08/2010] [Accepted: 05/03/2010] [Indexed: 01/16/2023]
Abstract
Histone acetylation is a key modification that regulates chromatin accessibility. Here we show that treatment with butyrate or other histone deacetylase (HDAC) inhibitors does not induce histone hyperacetylation in metaphase-arrested HeLa cells. When compared to similarly treated interphase cells, acetylation levels are significantly decreased in all four core histones and at all individual sites examined. However, the extent of the decrease varies, ranging from only slight reduction at H3K23 and H4K12 to no acetylation at H3K27 and barely detectable acetylation at H4K16. Our results show that the bulk effect is not due to increased or butyrate-insensitive HDAC activity, though these factors may play a role with some individual sites. We conclude that the lack of histone acetylation during mitosis is primarily due to changes in histone acetyltransferases (HATs) or changes in chromatin. The effects of protein phosphatase inhibitors on histone acetylation in cell lysates suggest that the reduced ability of histones to become acetylated in mitotic cells depends on protein phosphorylation.
Collapse
Affiliation(s)
- Jason S Patzlaff
- Department of Chemistry, University of Wisconsin-Oshkosh, 800 Algoma Blvd, Oshkosh, WI 54901, USA.
| | | | | | | | | |
Collapse
|
158
|
Abstract
Hypoxia is an integral component of the inflamed tissue microenvironment. Today, the influence of hypoxia on the natural evolution of inflammatory responses is widely accepted; however, many molecular and cellular mechanisms mediating this relationship remain to be clarified. Hypoxic stress affects several independent transcriptional regulators related to inflammation in which HIF-1 and NF-kappaB play central roles. Transcription factors interact with both HATs and HDACs, which are components of large multiprotein co-regulatory complexes. This review summarizes the current knowledge on hypoxia-responsive transcriptional pathways in inflammation and their importance in the etiology of chronic inflammatory diseases, with the primary focus on transcriptional co-regulators and histone modifications in defining gene-specific transcriptional responses in hypoxia, and on the recent progress in the understanding of hypoxia-mediated epigenetic reprogramming. Furthermore, this review discusses the molecular cross-talk between glucocorticoid anti-inflammatory pathways and hypoxia.
Collapse
Affiliation(s)
- O Safronova
- Department of Cellular Physiological Chemistry, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8549, Japan
| | | |
Collapse
|
159
|
Kong Q, Zeng W, Wu J, Hu W, Li C, Mao B. RNF220, an E3 ubiquitin ligase that targets Sin3B for ubiquitination. Biochem Biophys Res Commun 2010; 393:708-13. [DOI: 10.1016/j.bbrc.2010.02.066] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2010] [Accepted: 02/10/2010] [Indexed: 01/22/2023]
|
160
|
Oehme I, Deubzer HE, Lodrini M, Milde T, Witt O. Targeting of HDAC8 and investigational inhibitors in neuroblastoma. Expert Opin Investig Drugs 2010; 18:1605-17. [PMID: 19780707 DOI: 10.1517/14728220903241658] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Histone deacetylase (HDAC) inhibitors are an emerging class of promising novel anticancer drugs. However, little is known which one of the 11 classical HDAC family members is the most relevant drug target for therapy. The first Phase I/II trials show that unselective inhibition of HDACs causes a variety of side effects. Therefore, identification and selective targeting of the most critical tumor entity-relevant HDAC family member may reduce unspecific effects and increase antitumor efficacy in the future. Here, we review the clinical relevance of a particular HDAC family member, HDAC8, in neuroblastoma biology, a highly malignant embryonal childhood cancer. HDAC8 expression correlates with poor outcome in neuroblastoma and selective HDAC8 inhibition induces differentiation. In contrast, the targeting of other HDAC family members results in a completely different phenotype. Because HDAC8-selective inhibitors are available, HDAC8 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
Collapse
Affiliation(s)
- Ina Oehme
- German Cancer Research Center, CCU Pediatric Oncology, INF 280, D-69120 Heidelberg, Germany.
| | | | | | | | | |
Collapse
|
161
|
|
162
|
|
163
|
Wang L, de Zoeten EF, Greene MI, Hancock WW. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 2009; 8:969-81. [PMID: 19855427 PMCID: PMC2884987 DOI: 10.1038/nrd3031] [Citation(s) in RCA: 148] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Classical zinc-dependent histone deacetylases (HDACs) catalyse the removal of acetyl groups from histone tails and also from many non-histone proteins, including the transcription factor FOXP3, a key regulator of the development and function of regulatory T cells. Many HDAC inhibitors are in cancer clinical trials, but a subset of HDAC inhibitors has important anti-inflammatory or immunosuppressive effects that might be of therapeutic benefit in immuno-inflammatory disorders or post-transplantation. At least some of these effects result from the ability of HDAC inhibitors to enhance the production and suppressive functions of FOXP3(+) regulatory T cells. Understanding which HDACs contribute to the regulation of the functions of regulatory T cells may further stimulate the development of new class- or subclass-specific HDAC inhibitors with applications beyond oncology.
Collapse
Affiliation(s)
- Liqing Wang
- Division of Transplant Immunology, Children's Hospital of Philadelphia, Philadelphia 19104, USA
| | | | | | | |
Collapse
|
164
|
Charron CE, Chou PC, Coutts DJC, Kumar V, To M, Akashi K, Pinhu L, Griffiths M, Adcock IM, Barnes PJ, Ito K. Hypoxia-inducible factor 1alpha induces corticosteroid-insensitive inflammation via reduction of histone deacetylase-2 transcription. J Biol Chem 2009; 284:36047-36054. [PMID: 19880520 DOI: 10.1074/jbc.m109.025387] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Corticosteroids are potent anti-inflammatory agents, but corticosteroid insensitivity is a major barrier for the treatment of some chronic inflammatory diseases. Here, we show that hypoxia induces corticosteroid-insensitive inflammation via reduced transcription of histone deacetylase-2 (HDAC2) in lung epithelial and macrophage cells. HDAC2 mRNA and protein expression was reduced under hypoxic conditions (1% O(2)). Hypoxia enhanced interleukin-1beta-induced interleukin-8 (CXCL8) production in A549 cells and decreased the ability of dexamethasone to suppress the CXCL8 production. Deletion or point mutation studies revealed that binding of the transcription factor hypoxia-inducible factor (HIF) 1alpha to a HIF response element at position -320, but not HIF-1beta or HIF-2alpha, results in reduced polymerase II binding at the site, leading to reduced promoter activity of HDAC2. Our results suggest that activation of HIF-1alpha by hypoxia decreases HDAC2 levels, resulting in amplified inflammation and corticosteroid resistance.
Collapse
Affiliation(s)
- Catherine E Charron
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom.
| | - Pai-Chien Chou
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei 10507, Taiwan
| | - David J C Coutts
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom
| | - Vaibhav Kumar
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom
| | - Masako To
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom
| | - Kenichi Akashi
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom
| | - Liao Pinhu
- Unit of Critical Care, Imperial College Royal Brompton Hospital Campus, London SW3 6NP, United Kingdom
| | - Mark Griffiths
- Unit of Critical Care, Imperial College Royal Brompton Hospital Campus, London SW3 6NP, United Kingdom
| | - Ian M Adcock
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom
| | - Peter J Barnes
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom
| | - Kazuhiro Ito
- Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London SW3 6LY, United Kingdom
| |
Collapse
|
165
|
Cichewicz RH. Epigenome manipulation as a pathway to new natural product scaffolds and their congeners. Nat Prod Rep 2009; 27:11-22. [PMID: 20024091 DOI: 10.1039/b920860g] [Citation(s) in RCA: 196] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The covalent modification of chromatin is an important control mechanism used by fungi to modulate the transcription of genes involved in secondary metabolite production. To date, both molecular-based and chemical approaches targeting histone and DNA posttranslational processes have shown great potential for rationally directing the activation and/or suppression of natural-product-encoding gene clusters. In this Highlight, the organization of the fungal epigenome is summarized and strategies for manipulating chromatin-related targets are presented. Applications of these techniques are illustrated using several recently published accounts in which chemical-epigenetic methods and mutant studies were successfully employed for the de novo or enhanced production of structurally diverse fungal natural products (e.g., anthraquinones, cladochromes, lunalides, mycotoxins, and nygerones).
Collapse
Affiliation(s)
- Robert H Cichewicz
- Natural Products Discovery Group and Graduate Program in Ecology and Evolutionary Biology, Department of Chemistry and Biochemistry, 620 Parrington Oval, Room 208, University of Oklahoma, Norman, OK 73019, USA.
| |
Collapse
|
166
|
Abstract
The role of histone deacetylases (HDAC) and the potential of these enzymes as therapeutic targets for cancer, neurodegenerative diseases and a number of other disorders is an area of rapidly expanding investigation. There are 18 HDACs in humans. These enzymes are not redundant in function. Eleven of the HDACs are zinc dependent, classified on the basis of homology to yeast HDACs: Class I includes HDACs 1, 2, 3, and 8; Class IIA includes HDACs 4, 5, 7, and 9; Class IIB, HDACs 6 and 10; and Class IV, HDAC 11. Class III HDACs, sirtuins 1-7, have an absolute requirement for NAD(+), are not zinc dependent and generally not inhibited by compounds that inhibit zinc dependent deacetylases. In addition to histones, HDACs have many nonhistone protein substrates which have a role in regulation of gene expression, cell proliferation, cell migration, cell death, and angiogenesis. HDAC inhibitors (HDACi) have been discovered of different chemical structure. HDACi cause accumulation of acetylated forms of proteins which can alter their structure and function. HDACi can induce different phenotypes in various transformed cells, including growth arrest, apoptosis, reactive oxygen species facilitated cell death and mitotic cell death. Normal cells are relatively resistant to HDACi induced cell death. Several HDACi are in various stages of development, including clinical trials as monotherapy and in combination with other anti-cancer drugs and radiation. The first HDACi approved by the FDA for cancer therapy is suberoylanilide hydroxamic acid (SAHA, vorinostat, Zolinza), approved for treatment of cutaneous T-cell lymphoma.
Collapse
Affiliation(s)
- P A Marks
- Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
| | | |
Collapse
|
167
|
Luo Y, Jian W, Stavreva D, Fu X, Hager G, Bungert J, Huang S, Qiu Y. Trans-regulation of histone deacetylase activities through acetylation. J Biol Chem 2009; 284:34901-10. [PMID: 19822520 DOI: 10.1074/jbc.m109.038356] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
HDAC1 and -2 are highly conserved enzymes and often coexist in the same coregulator complexes. Understanding the regulation of histone deacetylase activities is extremely important because these enzymes play key roles in epigenetic regulation in normal and cancer cells. We previously showed that HDAC1 is required for glucocorticoid receptor-mediated transcription activation and that its activity is regulated through acetylation by p300 during the induction cycle. Here, we showed that HDAC2 is also required for glucocorticoid receptor-mediated gene activation. HDAC2, however, is regulated through a different mechanism from that of HDAC1. HDAC2 is not acetylated by p300, although 5 of 6 acetylated lysine residues in HDAC1 are also present in HDAC2. More importantly, the activity of HDAC2 is inhibited by acetylated HDAC1. Additionally, we showed that acetylated HDAC1 can trans-regulate HDAC2 through heterodimerization. Thus, this study uncovered fundamental differences between HDAC1 and HDAC2. It also unveiled a new mechanism of collaborative regulation by HDAC1/2 containing coregulator complexes.
Collapse
Affiliation(s)
- Yi Luo
- Department of Anatomy and Cell Biology, University of Florida, Gainesville, Florida 32610, USA
| | | | | | | | | | | | | | | |
Collapse
|
168
|
The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia 2009; 23:2265-74. [PMID: 19812608 DOI: 10.1038/leu.2009.182] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Acute myeloid leukemia (AML) is a clonal disorder characterized by the accumulation of myeloid blasts in the bone marrow. Here, we report the effects of the novel histone deacetylase inhibitor panobinostat (LBH589) in combination with doxorubicin on AML cells. Panobinostat exhibited potent anti-AML activity in all AML cell lines tested and in primary AML cells from patients (IC(50)<20 nM). In addition, panobinostat potentiated the action of several standard-of-care anti-AML compounds, particularly, doxorubicin. The molecular effects induced by panobinostat and doxorubicin treatment were investigated by analyzing gene expression, cell cycle, apoptosis and signaling pathways. Analyses of gene expression profiles identified 588 genes whose expression was exclusively affected by the combination of panobinostat and doxorubicin. The combination induced AML cell death by an increase in the mitochondrial outer membrane permeability and release of cytochrome c from the mitochondria, resulting in caspase-dependent apoptosis and accompanied by the upregulation of Bax, Bak and, particularly, Bad. The drug combination provoked a strong activation of a DNA damage response, indicating that this combination may trigger cell death by a mechanism that induced DNA double-strand breaks. These data indicate that the combination of panobinostat and doxorubicin may be an effective therapy for the treatment of AML.
Collapse
|
169
|
NF-kappaB activity is constitutively elevated in c-Abl null fibroblasts. Proc Natl Acad Sci U S A 2009; 106:17823-8. [PMID: 19805123 DOI: 10.1073/pnas.0905935106] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The c-abl proto-oncogene encodes a nonreceptor tyrosine kinase involved in many cellular processes, including signaling from growth factor and antigen receptors, remodeling the cytoskeleton, and responding to DNA damage and oxidative stress. Many downstream pathways are affected by c-Abl. Elevated c-Abl kinase activity can inhibit NF-kappaB activity by stabilizing the inhibitory protein IkappaB alpha, raising the possibility that c-Abl-deficient cells might have increased NF-kappaB activity. We examined the levels of NF-kappaB activity in primary mouse embryonic fibroblasts (MEFs) derived from wild-type and c-Abl knockout mice and found that the knockout MEFs indeed exhibited elevated NF-kappaB activity in response to stimulation as well as constitutively elevated NF-kappaB activity. Thus, endogenous c-Abl is a negative regulator of basal and inducible NF-kappaB activity. Examination of various points of NF-kappaB regulation revealed that unstimulated c-Abl knockout MEFs do not exhibit an increase in IkappaB alpha degradation, p65/RelA nuclear translocation, or DNA binding of NF-kappaB subunits. They do, however, show reduced levels of the histone deacetylase HDAC1, a negative regulator of basal NF-kappaB activity. Unstimulated c-Abl knockout MEFs are less responsive to induction of NF-kappaB activity by trichostatin A, an HDAC inhibitor, suggesting that c-Abl might play a role in the HDAC-mediated repression of basal NF-kappaB activity.
Collapse
|
170
|
Abstract
In this study, high-throughput microRNA (miRNA) expression analysis revealed that the expression of miR-140 was associated with chemosensitivity in osteosarcoma tumor xenografts. Tumor cells ectopically transfected with miR-140 were more resistant to methotrexate and 5-fluorouracil (5-FU). Overexpression of miR-140 inhibited cell proliferation in both osteosarcoma U-2 OS (wt-p53) and colon cancer HCT 116 (wt-p53) cell lines, but less so in osteosarcoma MG63 (mut-p53) and colon cancer HCT 116 (null-p53) cell lines. miR-140 induced p53 and p21 expression accompanied with G(1) and G(2) phase arrest only in cell lines containing wild type of p53. Histone deacetylase 4 (HDAC4) was confirmed to be one of the important targets of miR-140. The expression of endogenous miR-140 was significantly elevated in CD133(+hi)CD44(+hi) colon cancer stem-like cells that exhibit slow proliferating rate and chemoresistance. Blocking endogenous miR-140 by locked nucleic acid-modified anti-miR partially sensitized resistant colon cancer stem-like cells to 5-FU treatment. Taken together, our findings indicate that miR-140 is involved in the chemoresistance by reduced cell proliferation through G(1) and G(2) phase arrest mediated in part through the suppression of HDAC4. miR-140 may be a candidate target to develop novel therapeutic strategy to overcome drug resistance.
Collapse
|
171
|
Lee S, Park JR, Seo MS, Roh KH, Park SB, Hwang JW, Sun B, Seo K, Lee YS, Kang SK, Jung JW, Kang KS. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif 2009; 42:711-20. [PMID: 19689470 DOI: 10.1111/j.1365-2184.2009.00633.x] [Citation(s) in RCA: 116] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
OBJECTIVES Histone deacetylase (HDAC) is an important therapeutic target in cancer. Two of the main anticancer mechanisms of HDAC inhibitors are induction of terminal differentiation and inhibition of cell proliferation. To investigate the role of HDAC in maintenance of self-renewal and cell proliferation, we treated mesenchymal stem cells (MSCs) that originated from adipose tissue or umbilical cord blood with valproic acid (VPA) and sodium butyrate (NaBu). MATERIALS AND METHODS Human MSCs were isolated from mammary fat tissue and cord blood. We performed MTT assay and flow cytometry-based cell cycle analysis to assess self-renewal of MSCs. In vitro differentiation assays into osteogenic, adipogenic, neurogenic and chondrogenic lineages were conducted to investigate MSC multipotency. Immunocytochemistry, Western blot and reverse transcription-polymerase chain reaction were used to interrogate molecular pathways. RESULTS VPA and NaBu flattened the morphology of MSCs and inhibited their growth. VPA and NaBu activated the transcription of p21(CIP1/WAF1) by increasing the acetylation of histone H3 and H4 and eventually blocked the cell cycle at G2/M phase. The expression level of p16(INK4A), a cdk inhibitor that is closely related to cellular senescence, was not changed by HDAC inhibitor treatment. We performed controlled differentiation into bone, fat, cartilage and nervous tissue to elucidate the role of HDAC in the pluripotency of MSC to differentiate into functional tissues. VPA and NaBu decreased the efficiency of adipogenic, chondrogenic, and neurogenic differentiation as visualized by specific staining and reverse transcription-polymerase chain reaction. In contrast, osteogenic differentiation was elevated by HDAC inhibitor treatment. CONCLUSION HDAC activity is essential for maintaining the self-renewal and pluripotency of MSCs.
Collapse
Affiliation(s)
- S Lee
- Adult Stem Cell Research Center, Seoul National University, Seoul, South Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
172
|
Benson SA, Ernst JD. TLR2-dependent inhibition of macrophage responses to IFN-gamma is mediated by distinct, gene-specific mechanisms. PLoS One 2009; 4:e6329. [PMID: 19629181 PMCID: PMC2710511 DOI: 10.1371/journal.pone.0006329] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2009] [Accepted: 06/22/2009] [Indexed: 11/22/2022] Open
Abstract
Mycobacterium tuberculosis uses multiple mechanisms to avoid elimination by the immune system. We have previously shown that M. tuberculosis can inhibit selected macrophage responses to IFN-γ through TLR2-dependent and -independent mechanisms. To specifically address the role of TLR2 signaling in mediating this inhibition, we stimulated macrophages with the specific TLR2/1 ligand Pam3CSK4 and assayed responses to IFN-γ. Pam3CSK4 stimulation prior to IFN-γ inhibited transcription of the unrelated IFN-γ-inducible genes, CIITA and CXCL11. Surface expression of MHC class II and secretion of CXCL11 were greatly reduced as well, indicating that the reduction in transcripts had downstream effects. Inhibition of both genes required new protein synthesis. Using chromatin immunoprecipitation, we found that TLR2 stimulation inhibited IFN-γ-induced RNA polymerase II binding to the CIITA and CXCL11 promoters. Furthermore, TATA binding protein was unable to bind the TATA box of the CXCL11 promoter, suggesting that assembly of transcriptional machinery was disrupted. However, TLR2 stimulation affected chromatin modifications differently at each of the inhibited promoters. Histone H3 and H4 acetylation was reduced at the CIITA promoter but unaffected at the CXCL11 promoter. In addition, NF-κB signaling was required for inhibition of CXCL11 transcription, but not for inhibition of CIITA. Taken together, these results indicate that TLR2-dependent inhibition of IFN-γ-induced gene expression is mediated by distinct, gene-specific mechanisms that disrupt binding of the transcriptional machinery to the promoters.
Collapse
Affiliation(s)
- Sarah A. Benson
- Department of Medicine, Division of Infectious Diseases, New York University School of Medicine, New York, New York, United States of America
- Department of Microbiology, New York University School of Medicine, New York, New York, United States of America
| | - Joel D. Ernst
- Department of Medicine, Division of Infectious Diseases, New York University School of Medicine, New York, New York, United States of America
- Department of Microbiology, New York University School of Medicine, New York, New York, United States of America
- Department of Pathology, New York University School of Medicine, New York, New York, United States of America
- * E-mail:
| |
Collapse
|
173
|
Joanna F, van Grunsven LA, Mathieu V, Sarah S, Sarah D, Karin V, Tamara V, Vera R. Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology. J Cell Mol Med 2009; 13:2990-3005. [PMID: 19583816 PMCID: PMC4516460 DOI: 10.1111/j.1582-4934.2009.00831.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The transcriptional activity of genes largely depends on the accessibility of specific chromatin regions to transcriptional regulators. This process is controlled by diverse post-transcriptional modifications of the histone amino termini of which reversible acetylation plays a vital role. Histone acetyltransferases (HATs) are responsible for the addition of acetyl groups and histone deacetylases (HDACs) catalyse the reverse reaction. In general, though not exclusively, histone acetylation is associated with a positive regulation of transcription, whereas histone deacetylation is correlated with transcriptional silencing. The elucidation of unequivocal links between aberrant action of HDACs and tumorigenesis lies at the base of key scientific importance of these enzymes. In particular, the potential benefit of HDAC inhibition has been confirmed in various tumour cell lines, demonstrating antiproliferative, differentiating and pro-apoptotic effects. Consequently, the dynamic quest for HDAC inhibitors (HDIs) as a new class of anticancer drugs was set off, resulting in a number of compounds that are currently evaluated in clinical trials. Ironically, the knowledge with respect to the expression pattern and function of individual HDAC isoenzymes remains largely elusive. In the present review, we provide an update of the current knowledge on the involvement of HDACs in the regulation of fundamental cellular processes in the liver, being the main site for drug metabolism within the body. Focus lies on the involvement of HDACs in the regulation of growth of normal and transformed hepatocytes and the transdifferentiation process of stellate cells. Furthermore, extrapolation of our present knowledge on HDAC functionality towards innovative treatment of malignant and non-malignant, hyperproliferative and inflammatory disorders is discussed.
Collapse
Affiliation(s)
- Fraczek Joanna
- Department of Toxicology, Vrije Universiteit Brussel, Laarbeeklaan, Brussels, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
174
|
Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, Woodman B, Bates GP. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS One 2009; 4:e5747. [PMID: 19484127 PMCID: PMC2684627 DOI: 10.1371/journal.pone.0005747] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2009] [Accepted: 05/06/2009] [Indexed: 12/19/2022] Open
Abstract
Huntington's disease (HD) is an inherited, progressive neurological disorder caused by a CAG/polyglutamine repeat expansion, for which there is no effective disease modifying therapy. In recent years, transcriptional dysregulation has emerged as a pathogenic process that appears early in disease progression. Administration of histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) have consistently shown therapeutic potential in models of HD, at least partly through increasing the association of acetylated histones with down-regulated genes and by correcting mRNA abnormalities. The HDAC enzyme through which SAHA mediates its beneficial effects in the R6/2 mouse model of HD is not known. Therefore, we have embarked on a series of genetic studies to uncover the HDAC target that is relevant to therapeutic development for HD. HDAC7 is of interest in this context because SAHA has been shown to decrease HDAC7 expression in cell culture systems in addition to inhibiting enzyme activity. After confirming that expression levels of Hdac7 are decreased in the brains of wild type and R6/2 mice after SAHA administration, we performed a genetic cross to determine whether genetic reduction of Hdac7 would alleviate phenotypes in the R6/2 mice. We found no improvement in a number of physiological or behavioral phenotypes. Similarly, the dysregulated expression levels of a number of genes of interest were not improved suggesting that reduction in Hdac7 does not alleviate the R6/2 HD-related transcriptional dysregulation. Therefore, we conclude that the beneficial effects of HDAC inhibitors are not predominantly mediated through the inhibition of HDAC7.
Collapse
Affiliation(s)
- Caroline L. Benn
- Department of Medical and Molecular Genetics, King's College London School of Medicine, King's College London, London, United Kingdom
- Pfizer Regenerative Medicine, UCB Granta Park, Great Abington, Cambridge, United Kingdom
| | - Rachel Butler
- Department of Medical and Molecular Genetics, King's College London School of Medicine, King's College London, London, United Kingdom
- Nuffield Laboratory of Ophthalmology, University of Oxford, The John Radcliffe Hospital, Oxford, United Kingdom
| | - Lydia Mariner
- Department of Medical and Molecular Genetics, King's College London School of Medicine, King's College London, London, United Kingdom
| | - Jude Nixon
- Department of Medical and Molecular Genetics, King's College London School of Medicine, King's College London, London, United Kingdom
| | - Hilary Moffitt
- Department of Medical and Molecular Genetics, King's College London School of Medicine, King's College London, London, United Kingdom
| | - Michal Mielcarek
- Department of Medical and Molecular Genetics, King's College London School of Medicine, King's College London, London, United Kingdom
| | - Ben Woodman
- Department of Medical and Molecular Genetics, King's College London School of Medicine, King's College London, London, United Kingdom
| | - Gillian P. Bates
- Department of Medical and Molecular Genetics, King's College London School of Medicine, King's College London, London, United Kingdom
- * E-mail:
| |
Collapse
|
175
|
Illi B, Colussi C, Grasselli A, Farsetti A, Capogrossi MC, Gaetano C. NO sparks off chromatin: tales of a multifaceted epigenetic regulator. Pharmacol Ther 2009; 123:344-52. [PMID: 19464317 DOI: 10.1016/j.pharmthera.2009.05.003] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2009] [Accepted: 05/11/2009] [Indexed: 10/20/2022]
Abstract
The discovery of nitric oxide (NO) revealed its ambiguous nature, which is related to its pleiotropic activities that control the homeostasis of every organism from bacteria to mammals in several physiological and pathological situations. The wide range of action of NO basically depends on two features: 1) the variety of chemical reactions depending on NO, and 2) the differential cellular responses elicited by distinct NO concentrations. Despite the increasing body of knowledge regarding its chemistry, biology and NO-dependent signaling pathways, little information is available on the nuclear actions of NO in terms of gene expression regulation. Indeed, studies of a putative role for this diatomic compound in regulating chromatin remodeling are still in their infancy. Only recently has the role of NO in epigenetics emerged, and some of its putative epigenetic properties are still only hypothetical. In the present review, we discuss the current evidence for NO-related mechanisms of epigenetic gene expression regulation. We link some of the well known NO chemical reactions and metabolic processes (e.g., S-nitrosylation of thiols, tyrosine nitration, cGMP production) to chromatin modification and address the most recent, striking hypothesis about NO and the control of chromosomes structure.
Collapse
Affiliation(s)
- Barbara Illi
- Laboratorio di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino-IRCCS, Milan, Italy
| | | | | | | | | | | |
Collapse
|
176
|
Zhao HL, Ueki N, Marcelain K, Hayman MJ. The Ski protein can inhibit ligand induced RARalpha and HDAC3 degradation in the retinoic acid signaling pathway. Biochem Biophys Res Commun 2009; 383:119-24. [PMID: 19341714 DOI: 10.1016/j.bbrc.2009.03.141] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2009] [Accepted: 03/22/2009] [Indexed: 01/31/2023]
Abstract
Recent data has implicated the Ski protein as being a physiologically relevant negative regulator of signaling by retinoic acid (RA). The mechanism by which Ski represses RA signaling is unknown. Co-immunoprecipitation and immunofluorescence assay showed that Ski and RARalpha are in the same complex in both the absence and presence of RA, which makes Ski different from other corepressors. We determined that Ski can stabilize RARalpha and HDAC3. These results suggest that Ski represses RA signaling by stabilizing corepressor complex.
Collapse
Affiliation(s)
- Hong-Ling Zhao
- Department of Molecular Genetics and Microbiology, SUNY at Stony Brook, NY 11794-5222, USA
| | | | | | | |
Collapse
|
177
|
Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009; 280:211-21. [PMID: 19289255 DOI: 10.1016/j.canlet.2009.02.013] [Citation(s) in RCA: 175] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2009] [Accepted: 02/09/2009] [Indexed: 11/23/2022]
Abstract
Histone deacetylases (HDACs) have emerged as attractive drug targets, particularly for neoplastic indications. This large family is divided into four classes, of which three consist of zinc-dependent enzymes, and inhibitors of these are the subject of this review. Currently, there are several inhibitors advancing through clinical trials, all of which inhibit multiple isoforms of these three classes. While promising, these compounds have exhibited toxicities in the clinic that might limit their potential, particularly in solid tumors. It may be possible to reduce some of the toxicity by specifically targeting only the isoform(s) involved in maintaining that particular tumor and spare other isoforms that are uninvolved or even beneficial. This review examines the selectivity and toxicity of HDAC inhibitors currently in clinic, comparing pan-HDAC inhibitors to Class I selective compounds. The rationale for isoform-specific inhibitors is examined. The current status of isoform-specific inhibitor development is analyzed, especially inhibitors of HDAC1, 2, 4 and 8 enzymes, and the potential clinical utility of these compounds is discussed.
Collapse
|
178
|
Yang Z, Tang H, Huang H, Deng H. RTA promoter demethylation and histone acetylation regulation of murine gammaherpesvirus 68 reactivation. PLoS One 2009; 4:e4556. [PMID: 19234612 PMCID: PMC2644783 DOI: 10.1371/journal.pone.0004556] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2008] [Accepted: 01/15/2009] [Indexed: 01/24/2023] Open
Abstract
Gammaherpesviruses have a common biological characteristic, latency and lytic replication. The balance between these two phases in murine gammaherpesvirus 68 (MHV-68) is controlled by the replication and transcription activator (RTA) gene. In this report, we investigated the effect of DNA demethylation and histone acetylation on MHV-68 replication. We showed that distinctive methylation patterns were associated with MHV-68 at the RTA promoter during latency or lytic replication. Treatment of MHV-68 latently-infected S11E cells with a DNA methyltransferases (DNMTs) inhibitor 5-azacytidine (5-AzaC), only weakly reactivated MHV-68, despite resulted in demethylation of the viral RTA promoter. In contrast, treatment with a histone deacetylase (HDAC) inhibitor trichostatin A (TSA) strongly reactivated MHV-68 from latency, and this was associated with significant change in histone H3 and H4 acetylation levels at the RTA promoter. We further showed that HDAC3 was recruited to the RTA promoter and inhibited RTA transcription during viral latency. However, TSA treatment caused rapid removal of HDAC3 and also induced passive demethylation at the RTA promoter. In vivo, we found that the RTA promoter was hypomethylated during lytic infection in the lung and that methylation level increased with virus latent infection in the spleen. Collectively, our data showed that histone acetylation, but not DNA demethylation, is sufficient for effective reactivation of MHV-68 from latency in S11E cells.
Collapse
Affiliation(s)
- Zhangsheng Yang
- Center for Infection and Immunity and National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- Graduate School of the Chinese Academy of Sciences, Beijing, China
| | - Haidong Tang
- Center for Infection and Immunity and National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- Graduate School of the Chinese Academy of Sciences, Beijing, China
| | - Hai Huang
- Center for Infection and Immunity and National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- Graduate School of the Chinese Academy of Sciences, Beijing, China
| | - Hongyu Deng
- Center for Infection and Immunity and National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
- School of Dentistry, University of California Los Angeles, Los Angeles, California, United States of America
- * E-mail:
| |
Collapse
|
179
|
Zschoernig B, Mahlknecht U. Carboxy-terminal phosphorylation of SIRT1 by protein kinase CK2. Biochem Biophys Res Commun 2009; 381:372-7. [PMID: 19236849 DOI: 10.1016/j.bbrc.2009.02.085] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2009] [Accepted: 02/07/2009] [Indexed: 10/21/2022]
Abstract
Previous analyses of the sirtuin family of histone deacetylases and its most prominent member SIRT1 have focused primarily on the identification of cellular targets exploring the underlying molecular mechanisms of its implicated function in the control of metabolic homeostasis, differentiation, apoptosis and cell survival. So far, little is known about the regulation of SIRT1 itself. In the study presented herein, we assigned the main region of SIRT1 in vivo phosphorylation to amino acids 643-691 of the unique carboxy-terminal domain. Furthermore, we demonstrate that SIRT1 is a substrate for protein kinase CK2 both in vitro and in vivo. Both, deletion construct analyses and serine-to-alanine mutations identified SIRT1 Ser-659 and Ser-661 as major CK2 phosphorylation sites that are phosphorylated in vivo as well.
Collapse
Affiliation(s)
- Barbara Zschoernig
- Saarland University Medical Center, Department of Internal Medicine, Division of Immunotherapy and Gene Therapy, D-66421 Homburg/Saar, Germany
| | | |
Collapse
|
180
|
Histone acetylation in drug addiction. Semin Cell Dev Biol 2009; 20:387-94. [PMID: 19560043 DOI: 10.1016/j.semcdb.2009.01.005] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2008] [Revised: 01/09/2009] [Accepted: 01/13/2009] [Indexed: 11/22/2022]
Abstract
Regulation of chromatin structure through post-translational modifications of histones (e.g., acetylation) has emerged as an important mechanism to translate a variety of environmental stimuli, including drugs of abuse, into specific changes in gene expression. Since alterations in gene expression are thought to contribute to the development and maintenance of the addicted state, recent efforts are aimed at identifying how drugs of abuse alter chromatin structure and the enzymes which regulate it. This review discusses how drugs of abuse alter histone acetylation in brain reward regions, through which enzymes this occurs, and ultimately what role histone acetylation plays in addiction-related behaviors.
Collapse
|
181
|
Sule N, Singh R, Srivastava DK. Alternative Modes of Binding of Recombinant Human Histone Deacetylase 8 to Colloidal Gold Nanoparticles. J Biomed Nanotechnol 2008; 4:463-468. [PMID: 19956788 DOI: 10.1166/jbn.2008.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Histone deacetylases are intimately involved in the transcriptional regulation of genes, and they are high priority drug targets for cancer therapy. Due to prevalence of several sulfhydryl groups on the surface of histone deacetylase 8, we explored the possibility of its binding to colloidal gold nanoparticles by determining its potentials to inhibit the flocculation as well as retaining the enzyme activity. It was observed that although both these processes conformed to the binding affinity of the gold-histone deacetylase 8 conjugate as being equal to 15-20 nM, only 30% of the nanoparticle-bound enzyme exhibited the enzymatic activity. In the light of the structural features of histone deacetylase 8, we propose that the enzyme interacts with the gold nanoparticles via the surface exposed thiol groups, and such interaction occurs in two alternative modes. Whereas the enzyme bound via mode-1 is catalytically inactive (presumably due to the orientation of the enzyme's active site toward the gold nanoparticle surface), and it prevents the flocculation of the nanoparticles, the enzyme bound via mode-2 shows the full catalytic activity (as its active site is believed to be oriented away from the nanoparticle surface). Although the histone deacetylase 8 bound to AuNP via mode-2 exhibits the same inhibitory potency against Trichostatin A as the free enzyme, the former is more susceptible to thermal denaturation. The potential of potent interaction between gold nanoparticles and histone deacetylase 8 via alternative modes may find diagnostic and/or therapeutic applications for different forms of cancers.
Collapse
Affiliation(s)
- Nitesh Sule
- Department of Chemistry, Biochemistry and Molecular Biology, North Dakota State University, Fargo, ND 58105
| | | | | |
Collapse
|
182
|
Kee HJ, Eom GH, Joung H, Shin S, Kim JR, Cho YK, Choe N, Sim BW, Jo D, Jeong MH, Kim KK, Seo JS, Kook H. Activation of Histone Deacetylase 2 by Inducible Heat Shock Protein 70 in Cardiac Hypertrophy. Circ Res 2008; 103:1259-69. [DOI: 10.1161/01.res.0000338570.27156.84] [Citation(s) in RCA: 107] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Diverse cardiac diseases induce cardiac hypertrophy, which leads to dilatation and heart failure. We previously reported that hypertrophy can be blocked by class I histone deacetylase (HDAC) inhibitor, which prompted us to investigate the regulatory mechanism of class I HDACs. Cardiac hypertrophy was introduced by aortic banding, by infusion of isoproterenol or angiotensin II, or by swimming. Hypertrophic stimuli transiently elevated the activity of histone deacetylase-2 (Hdac2), a class I HDAC. In cardiomyocytes, forced expression of Hdac2 simulated hypertrophy in an Akt-dependent manner, whereas enzymatically inert Hdac2 H141A failed to do so. Hypertrophic stimuli induced the expression of heat shock protein (Hsp)70. The induced Hsp70 physically associated with and activated Hdac2. Hsp70 overexpression produced a hypertrophic phenotype, which was blocked either by siHdac2 or by a dominant negative Hsp70ΔABD. In
Hsp70.1
−/−
mice, cardiac hypertrophy and Hdac2 activation were significantly blunted. Heat shock either to cardiomyocytes or to mice activated Hdac2 and induced hypertrophy. However, heat shock-induced Hdac2 activation was blunted in the cardiomyocytes isolated from
Hsp70.1
−/−
mice. These results suggest that the induction of Hsp70 in response to diverse hypertrophic stresses and the ensuing activation of HDAC2 trigger cardiac hypertrophy, emphasizing HSP70/HDAC2 as a novel mechanism regulating hypertrophy.
Collapse
Affiliation(s)
- Hae Jin Kee
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Gwang Hyeon Eom
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Hosouk Joung
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Sera Shin
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Ju-Ryoung Kim
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Young Kuk Cho
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Nakwon Choe
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Bo-Woong Sim
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Daewoong Jo
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Myung Ho Jeong
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Kyung Keun Kim
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Jeong-Sun Seo
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| | - Hyun Kook
- From the Departments of Pharmacology (H.J.K., G.H.E., H.J., S.S., J.-R.K., N.C., K.K.K., H.K.), Biomedical Science (D.J.) and Medical Research Center for Gene Regulation (H.J.K., G.H.E., H.J., J.-R.K., K.K.K., H.K.), Chonnam National University Medical School, Gwangju; Department of Pediatrics (Y.K.C.), Heart Center (M.H.J.), Chonnam National University Hospital, Gwangju, South Korea; Macrogen Inc (B.-W.S., J.-S.S.) and Department of Biochemistry and Molecular Biology (J.-S.S.), Seoul National
| |
Collapse
|
183
|
Liu PY, Chan JYH, Lin HC, Wang SL, Liu ST, Ho CL, Chang LC, Huang SM. Modulation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by Zac1 through the antagonistic regulators p53 and histone deacetylase 1 in HeLa Cells. Mol Cancer Res 2008; 6:1204-14. [PMID: 18644983 DOI: 10.1158/1541-7786.mcr-08-0123] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Zac1 is a novel seven-zinc finger protein which possesses the ability to bind specifically to GC-rich DNA elements. Zac1 not only promotes apoptosis and cell cycle arrest but also acts as a transcriptional cofactor for p53 and a number of nuclear receptors. Our previous study indicated that the enhancement of p53 activity by Zac1 is much more pronounced in HeLa cells compared with other cell lines tested. This phenomenon might be due to the coactivator effect of Zac1 on p53 and the ability of Zac1 to reverse E6 inhibition of p53. In the present study, we showed that Zac1 acted synergistically with either p53 or a histone deacetylase inhibitor, trichostatin A, to enhance p21(WAF1/Cip1) promoter activity. We showed that Zac1 physically interacted with some nuclear receptor corepressors such as histone deacetylase 1 (HDAC1) and mSin3a, and the induction of p21(WAF1/Cip1) gene and protein by Zac1 was suppressed by either overexpressing HDAC1 or its deacetylase-dead mutant. In addition, our data suggest that trichostatin A-induced p21(WAF1/Cip1) protein expression might be mediated through a p53-independent and HDAC deacetylase-independent pathway. Taken together, our data suggest that Zac1 might be involved in regulating the p21(WAF1/Cip1) gene and protein expression through its protein-protein interaction with p53 and HDAC1 in HeLa cells.
Collapse
Affiliation(s)
- Pei-Yao Liu
- Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan, Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
184
|
Liu Z, Li T, Liu Y, Jia Z, Li Y, Zhang C, Chen P, Ma K, Affara N, Zhou C. WNT signaling promotes Nkx2.5 expression and early cardiomyogenesis via downregulation of Hdac1. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2008; 1793:300-11. [PMID: 18851995 DOI: 10.1016/j.bbamcr.2008.08.013] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/2008] [Revised: 08/17/2008] [Accepted: 08/28/2008] [Indexed: 02/06/2023]
Abstract
The cardiac transcription factor NKX2.5 plays a crucial role in cardiomyogenesis, but its mechanism of regulation is still unclear. Recently, epigenetic regulation has become increasingly recognized as important in differentiation and development. In this study, we used P19CL6 cells to investigate the regulation of Nkx2.5 expression by methylation and acetylation during cardiomyocyte differentiation. During the early stage of differentiation, Nkx2.5 expression was upregulated, but the methylation status of the Nkx2.5 promoter did not undergo significant change; while the acetylation levels of histones H3 and H4 were increased, accompanied by a significant reduction in Hdac1 expression. Suppression of Hdac1 activity stimulated cardiac differentiation accompanied by increased expression of cardiac-specific genes and cell cycle arrest. Overexpression of Hdac1 inhibited cardiomyocyte formation and downregulated the expressions of Gata4 and Nkx2.5. Mimicking induction of the WNT pathway inhibited Hdac1 expression with upregulated Nkx2.5 expression. WNT3a and WNT3 downregulated the expression of Hdac1, contrary to the effect of SFRP2 and GSK3beta. Cotransfection of beta-catenin and Lef1 significantly downregulated the expression of Hdac1. Our data suggest that WNT signaling pathway plays important roles in the regulation of Hdac1 during the early stage of cardiomyocyte differentiation and that the downregulation of Hdac1 promotes cardiac differentiation.
Collapse
Affiliation(s)
- Zhiqiang Liu
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University, 38 Xue Yuan Road, Hai Dian District, Beijing, 100191, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
185
|
Zschoernig B, Mahlknecht U. SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun 2008; 376:251-5. [PMID: 18774777 DOI: 10.1016/j.bbrc.2008.08.137] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2008] [Accepted: 08/26/2008] [Indexed: 10/21/2022]
Abstract
Earlier analyses on the sirtuin family of histone deacetylases and its well-known member SIRT1 had their primary focus mostly on the identification of cellular targets exploring molecular mechanisms and functional networks in the control of metabolic homeostasis, differentiation, apoptosis and cell survival. However, only little is known about the regulation of SIRT1 itself, so far. Presently, SIRT1 is gaining increasing importance in the development of innovative treatment strategies for cancer, neurodegenerative disorders and metabolic disease. Based on differences in their catalytic activities, SIRT1 and the sirtuins in general, are insensitive to the classical class I and II HDAC inhibitors which are increasingly becoming part of treatment regimens for solid tumors and hematological malignancies. In this review we outline recent research advances on the regulation of SIRT1 which may provide the basis for the development of therapeutic inhibitors with improved specificity.
Collapse
Affiliation(s)
- Barbara Zschoernig
- Saarland University Medical Center, Department of Internal Medicine, Division of Immunotherapy and Gene Therapy, José Carreras Center for Immunotherapy and Gene Therapy, Kirrberger Strasse, Building 40, D-66421 Homburg/Saar, Germany
| | | |
Collapse
|
186
|
Thorne JL, Campbell MJ, Turner BM. Transcription factors, chromatin and cancer. Int J Biochem Cell Biol 2008; 41:164-75. [PMID: 18804550 DOI: 10.1016/j.biocel.2008.08.029] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2008] [Revised: 08/15/2008] [Accepted: 08/18/2008] [Indexed: 01/26/2023]
Abstract
Transcription factors, chromatin and chromatin-modifying enzymes are key components in a complex network through which the genome interacts with its environment. For many transcription factors, binding motifs are found adjacent to the promoter regions of a large proportion of genes, requiring mechanisms that confer binding specificity in any given cell type. These include association of the factor with other proteins and packaging of DNA, as chromatin, at the binding sequence so as to inhibit or facilitate binding. Recent evidence suggests that specific post-translational modifications of the histones packaging promoter DNA can help guide transcription factors to selected sites. The enzymes that put such modifications in place are dependent on metabolic components (e.g. acetyl CoA, S-adenosyl methionine) and susceptible to inhibition or activation by environmental factors. Local patterns of histone modification can be altered or maintained through direct interaction between the transcription factor and histone modifying enzymes. The functional consequences of transcription factor binding are also dependent on protein modifying enzymes, particularly those that alter lysine methylation at selected residues. Remarkably, the role of these enzymes is not limited to promoter-proximal events, but can be linked to changes in the intranuclear location of target genes. In this review we describe results that begin to define how transcription factors, chromatin and environmental variables interact and how these interactions are subverted in cancer. We focus on the nuclear receptor family of transcription factors, where binding of ligands such as steroid hormones and dietary derived factors provides an extra level of environmental input.
Collapse
Affiliation(s)
- James L Thorne
- University of Birmingham Medical School, Edgbaston, Birmingham, B15 2TT, UK
| | | | | |
Collapse
|
187
|
Meja KK, Rajendrasozhan S, Adenuga D, Biswas SK, Sundar IK, Spooner G, Marwick JA, Chakravarty P, Fletcher D, Whittaker P, Megson IL, Kirkham PA, Rahman I. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 2008; 39:312-23. [PMID: 18421014 PMCID: PMC2542449 DOI: 10.1165/rcmb.2008-0012oc] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2008] [Accepted: 03/12/2008] [Indexed: 11/24/2022] Open
Abstract
Oxidative stress as a result of cigarette smoking is an important etiologic factor in the pathogenesis of chronic obstructive pulmonary disease (COPD), a chronic steroid-insensitive inflammatory disease of the airways. Histone deacetylase-2 (HDAC2), a critical component of the corticosteroid anti-inflammatory action, is impaired in lungs of patients with COPD and correlates with disease severity. We demonstrate here that curcumin (diferuloylmethane), a dietary polyphenol, at nanomolar concentrations specifically restores cigarette smoke extract (CSE)- or oxidative stress-impaired HDAC2 activity and corticosteroid efficacy in vitro with an EC(50) of approximately 30 nM and 200 nM, respectively. CSE caused a reduction in HDAC2 protein expression that was restored by curcumin. This decrease in HDAC2 protein expression was reversed by curcumin even in the presence of cycloheximide, a protein synthesis inhibitor. The proteasomal inhibitor, MG132, also blocked CSE-induced HDAC2 degradation, increasing the levels of ubiquitinated HDAC2. Biochemical and gene chip analysis indicated that curcumin at concentrations up to 1 muM propagates its effect via antioxidant-independent mechanisms associated with the phosphorylation-ubiquitin-proteasome pathway. Thus curcumin acts at a post-translational level by maintaining both HDAC2 activity and expression, thereby reversing steroid insensitivity induced by either CSE or oxidative stress in monocytes. Curcumin may therefore have potential to reverse steroid resistance, which is common in patients with COPD and asthma.
Collapse
Affiliation(s)
- Koremu K Meja
- Novartis Institutes for Biomedical Research, Respiratory Disease, Horsham, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
188
|
Ray S, Lee C, Hou T, Boldogh I, Brasier AR. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Res 2008; 36:4510-20. [PMID: 18611949 PMCID: PMC2490754 DOI: 10.1093/nar/gkn419] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor that plays a crucial role in interleukin-6 (IL-6) signaling, mediating the acute-phase induction of the human Angiotensinogen (hAGT) gene in hepatocytes. We showed earlier that IL-6 induces acetylation of the STAT3 NH2-terminus by the recruitment of the p300 coactivator. We had also observed a physical interaction of STAT3 and Histone Deacetylase1 (HDAC1) in an IL-6-dependent manner that leads to transcriptional repression. In this study, we sought to elucidate the mechanism by which HDAC1 controls STAT3 transcriptional activity. Here, we mapped the interacting domains of both STAT3 and HDAC1 and found that the COOH-terminal domain of HDAC1 is necessary for IL-6-induced STAT3 transcriptional repression, whereas the NH2-terminal acetylation domain of STAT3 is required for HDAC1 binding. Interestingly, over expression of HDAC1 in HepG2 cells leads to significantly reduced amounts of nuclear STAT3 after IL-6 induction, whereas silencing of HDAC1 resulted in accumulation of total and acetylated STAT3 in the nucleus. We have found that HDAC1 knockdown also interferes with the responsiveness of the STAT3-dependent MCP1 target gene expression to IL-6, as confirmed by real-time RT–PCR analysis. Together, our study reveals the novel functional consequences of IL-6-induced STAT3-HDAC1 interaction on nucleocytoplasmic distribution of STAT3.
Collapse
Affiliation(s)
- Sutapa Ray
- Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555-1060, USA.
| | | | | | | | | |
Collapse
|
189
|
Smith BC, Denu JM. Chemical mechanisms of histone lysine and arginine modifications. BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS 2008; 1789:45-57. [PMID: 18603028 DOI: 10.1016/j.bbagrm.2008.06.005] [Citation(s) in RCA: 267] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2008] [Accepted: 06/09/2008] [Indexed: 10/21/2022]
Abstract
Histone lysine and arginine residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination, and sumoylation. The combinatorial action of these modifications regulates critical DNA processes including replication, repair, and transcription. In addition, enzymes that modify histone lysine and arginine residues have been correlated with a variety of human diseases including arthritis, cancer, heart disease, diabetes, and neurodegenerative disorders. Thus, it is important to fully understand the detailed kinetic and chemical mechanisms of these enzymes. Here, we review recent progress towards determining the mechanisms of histone lysine and arginine modifying enzymes. In particular, the mechanisms of S-adenosyl-methionine (AdoMet) dependent methyltransferases, FAD-dependent demethylases, iron dependent demethylases, acetyl-CoA dependent acetyltransferases, zinc dependent deacetylases, NAD(+) dependent deacetylases, and protein arginine deiminases are covered. Particular attention is paid to the conserved active-site residues necessary for catalysis and the individual chemical steps along the catalytic pathway. When appropriate, areas requiring further work are discussed.
Collapse
Affiliation(s)
- Brian C Smith
- Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | | |
Collapse
|
190
|
Brasanac D, Boricic I, Todorovic V, Tomanovic N. Primary cutaneous carcinosarcoma: case report with expanded immunohistochemical analysis. Int J Dermatol 2008; 47:496-501. [DOI: 10.1111/j.1365-4632.2008.03427.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
191
|
Rajendrasozhan S, Yang SR, Edirisinghe I, Yao H, Adenuga D, Rahman I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal 2008; 10:799-811. [PMID: 18220485 PMCID: PMC2758554 DOI: 10.1089/ars.2007.1938] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Oxidative stress has been implicated in the pathogenesis of several inflammatory lung disorders including chronic obstructive pulmonary disease (COPD), due to its effect on pro-inflammatory gene transcription. Cigarette smoke-mediated oxidative stress activates NF-kappaB-dependent transcription of pro-inflammatory mediators either through activation of inhibitor kappaB-alpha kinase (IKK) and/or the enhanced recruitment and activation of transcriptional co-activators. Enhanced NF-kappaB-co-activator complex formation results in targeted increase in chromatin modifications, such as histone acetylation leading to inflammatory gene transcription. NF-kappaB-dependent gene expression, at least in part, is regulated by changes in deacetylases such as histone deacetylases (HDACs) and sirtuins. Cigarette smoke and oxidants also alter the activity of HDACs and sirtuins by post-translational modifications by protein carbonylation and nitration, and in doing so further induce gene expression of pro-inflammatory mediators by chromatin modifications. In addition, cigarette smoke/oxidants can reduce glucocorticoid sensitivity by attenuating HDAC2 activity and expression, which may account for the glucocorticoid insensitivity in patients with COPD. Understanding the mechanisms of NF-kappaB regulation, and the balance between histone acetylation and deacetylation may lead to the development of novel therapies based on the pharmacological manipulation of IKK and deacetylases in lung inflammation and injury.
Collapse
Affiliation(s)
- Saravanan Rajendrasozhan
- Department of Environmental Medicine, Lung Biology and Disease Program, University of Rochester Medical Center, Rochester, NY, USA
| | | | | | | | | | | |
Collapse
|
192
|
Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia 2008; 10:303-13. [PMID: 18392140 PMCID: PMC2288545 DOI: 10.1593/neo.07834] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2007] [Revised: 01/27/2008] [Accepted: 01/28/2008] [Indexed: 11/18/2022]
Abstract
The aim of this work was to use phosphorus magnetic resonance spectroscopy ((31)P MRS) to investigate the pharmacodynamic effects of LAQ824, a histone deacetylase (HDAC) inhibitor. Human HT29 colon carcinoma cells were examined by (31)P MRS after treatment with LAQ824 and another HDAC inhibitor, suberoylanilide hydroxamic acid. HT29 xenografts and tumor extracts were also examined using (31)P MRS, pre- and post-LAQ824 treatment. Histone H3 acetylation was determined using Western blot analysis, and tumor microvessel density by immunohistochemical staining of CD31. Phosphocholine showed a significant increase in HT29 cells after treatment with LAQ824 and suberoylanilide hydroxamic acid. In vivo, the ratio of phosphomonoester/total phosphorus (TotP) signal was significantly increased in LAQ824-treated HT29 xenografts, and this ratio was inversely correlated with changes in tumor volume. Statistically significant decreases in intracellular pH, beta-nucleoside triphosphate (beta-NTP)/TotP, and beta-NTP/inorganic phosphate (Pi) and an increase in Pi/TotP were also seen in LAQ824-treated tumors. Tumor extracts showed many significant metabolic changes after LAQ824 treatment, in parallel with increased histone acetylation and decreased microvessel density. Treatment with LAQ824 resulted in altered phospholipid metabolism and compromised tumor bioenergetics. The phosphocholine and phosphomonoester increases may have the potential to act as pharmacodynamic markers for noninvasively monitoring tumor response after treatment with LAQ824 or other HDAC inhibitors.
Collapse
Affiliation(s)
- Yuen-Li Chung
- Cancer Research UK, Biomedical Magnetic Resonance Research Group, Department of Basic Medical Sciences, St. George's University of London, London, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
193
|
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008; 111:5093-100. [PMID: 18349321 DOI: 10.1182/blood-2007-10-117762] [Citation(s) in RCA: 117] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We investigated the mechanism of action of LBH589, a novel broad-spectrum HDAC inhibitor belonging to the hydroxamate class, in Philadelphia chromosome-negative (Ph(-)) acute lymphoblastic leukemia (ALL). Two model human Ph(-) ALL cell lines (T-cell MOLT-4 and pre-B-cell Reh) were treated with LBH589 and evaluated for biologic and gene expression responses. Low nanomolar concentrations (IC(50): 5-20 nM) of LBH589 induced cell-cycle arrest, apoptosis, and histone (H3K9 and H4K8) hyperacetylation. LBH589 treatment increased mRNA levels of proapoptosis, growth arrest, and DNA damage repair genes including FANCG, FOXO3A, GADD45A, GADD45B, and GADD45G. The most dramatically expressed gene (up to 45-fold induction) observed after treatment with LBH589 is GADD45G. LBH589 treatment was associated with increased histone acetylation at the GADD45G promoter and phosphorylation of histone H2A.X. Furthermore, treatment with LBH589 was active against cultured primary Ph(-) ALL cells, including those from a relapsed patient, inducing loss of cell viability (up to 70%) and induction of GADD45G mRNA expression (up to 35-fold). Thus, LBH589 possesses potent growth inhibitory activity against including Ph(-) ALL cells associated with up-regulation of genes critical for DNA damage response and growth arrest. These findings provide a rationale for exploring the clinical activity of LBH589 in the treatment of patients with Ph(-) ALL.
Collapse
|
194
|
Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008; 9:206-18. [PMID: 18292778 DOI: 10.1038/nrm2346] [Citation(s) in RCA: 925] [Impact Index Per Article: 57.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Protein lysine deacetylases have a pivotal role in numerous biological processes and can be divided into the Rpd3/Hda1 and sirtuin families, each having members in diverse organisms including prokaryotes. In vertebrates, the Rpd3/Hda1 family contains 11 members, traditionally referred to as histone deacetylases (HDAC) 1-11, which are further grouped into classes I, II and IV. Whereas most class I HDACs are subunits of multiprotein nuclear complexes that are crucial for transcriptional repression and epigenetic landscaping, class II members regulate cytoplasmic processes or function as signal transducers that shuttle between the cytoplasm and the nucleus. Little is known about class IV HDAC11, although its evolutionary conservation implies a fundamental role in various organisms.
Collapse
Affiliation(s)
- Xiang-Jiao Yang
- Molecular Oncology Group, Department of Medicine, McGill University Health Center, Montréal, Québec, H3A 1A1, Canada.
| | | |
Collapse
|
195
|
Zimmermann S, Kiefer F, Prudenziati M, Spiller C, Hansen J, Floss T, Wurst W, Minucci S, Göttlicher M. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008; 67:9047-54. [PMID: 17909008 DOI: 10.1158/0008-5472.can-07-0312] [Citation(s) in RCA: 107] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The histone deacetylase (HDAC) family of transcriptional co-repressors have emerged as important regulators of colon cell maturation and transformation. Pharmacological inhibitors of class I and II HDAC activity (HDACi) are potent inducers of growth arrest, differentiation and apoptosis of colon cancer cells in vitro and in vivo, implicating a role for these HDACs in tumor promotion. Consistent with this role, expression of several HDACs are upregulated in colon tumors, while downregulation of specific HDACs inhibits growth of colon cancer cells in vitro and intestinal tumorigenesis in vivo. This review focuses on the function and transcriptional mechanisms by which class I and II HDACs regulate colon cell maturation and transformation, and on the mechanisms by which HDACi induce growth arrest, differentiation and apoptosis of colon cancer cells. The emerging role of the class III HDAC, Sirt1, in colon cancer progression is also discussed.
Collapse
Affiliation(s)
- Stephan Zimmermann
- Institute of Toxicology, GSF National Research Center for Environment and Health, Neuherberg, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
196
|
Abstract
The purpose of this paper was to selectively review the literature on the role of epigenetics in mental illnesses. Aberrant epigenetic regulation has been clearly implicated in the aetiology of some human illnesses. In recent years a growing body of evidence has highlighted the possibility that epigenetics may also play a key role in the origins and expression of mental disorders. Epigenetic phenomena may help explain some of the complexity of mental illnesses and provide a basis for discovering novel pharmacological targets to treat these disorders.
Collapse
|
197
|
Chromatin-bound p53 anchors activated Smads and the mSin3A corepressor to confer transforming-growth-factor-beta-mediated transcription repression. Mol Cell Biol 2008; 28:1988-98. [PMID: 18212064 DOI: 10.1128/mcb.01442-07] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
In hepatic cells, Smad and SnoN proteins converge with p53 to repress transcription of AFP, an oncodevelopmental tumor marker aberrantly reactivated in hepatoma cells. Using p53- and SnoN-depleted hepatoma cell clones, we define a mechanism for repression mediated by this novel transcriptional partnership. We find that p53 anchors activated Smads and the corepressor mSin3A to the AFP distal promoter. Sequential chromatin immunoprecipitation analyses and molecular modeling indicate that p53 and Smad proteins simultaneously occupy overlapping p53 and Smad regulatory elements to establish repression of AFP transcription. In addition to its well-known function in antagonizing transforming growth factor beta (TGF-beta) responses, we find that SnoN actively participates in AFP repression by positively regulating mSin3A protein levels. We propose that activation of TGF-beta signaling restores a dynamic interplay between p53 and TGF-beta effectors that cooperate to effectively target mSin3A to tumor marker AFP and reestablish transcription repression.
Collapse
|
198
|
Illi B, Russo CD, Colussi C, Rosati J, Pallaoro M, Spallotta F, Rotili D, Valente S, Ragone G, Martelli F, Biglioli P, Steinkuhler C, Gallinari P, Mai A, Capogrossi MC, Gaetano C. Nitric Oxide Modulates Chromatin Folding in Human Endothelial Cells via Protein Phosphatase 2A Activation and Class II Histone Deacetylases Nuclear Shuttling. Circ Res 2008; 102:51-8. [DOI: 10.1161/circresaha.107.157305] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Nitric oxide (NO) modulates important endothelial cell (EC) functions and gene expression by a molecular mechanism which is still poorly characterized. Here we show that in human umbilical vein ECs (HUVECs) NO inhibited serum-induced histone acetylation and enhanced histone deacetylase (HDAC) activity. By immunofluorescence and Western blot analyses it was found that NO induced class II HDAC4 and 5 nuclear shuttling and that class II HDACs selective inhibitor MC1568 rescued serum-dependent histone acetylation above control level in NO-treated HUVECs. In contrast, class I HDACs inhibitor MS27–275 had no effect, indicating a specific role for class II HDACs in NO-dependent histone deacetylation. In addition, it was found that NO ability to induce HDAC4 and HDAC5 nuclear shuttling involved the activation of the protein phosphatase 2A (PP2A). In fact, HDAC4 nuclear translocation was impaired in ECs expressing small-t antigen and exposed to NO. Finally, in cells engineered to express a HDAC4-Flag fusion protein, NO induced the formation of a macromolecular complex including HDAC4, HDAC3, HDAC5, and an active PP2A. The present results show that NO-dependent PP2A activation plays a key role in class II HDACs nuclear translocation.
Collapse
Affiliation(s)
- Barbara Illi
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Claudio Dello Russo
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Claudia Colussi
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Jessica Rosati
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Michele Pallaoro
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Francesco Spallotta
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Dante Rotili
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Sergio Valente
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Gianluca Ragone
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Fabio Martelli
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Paolo Biglioli
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Christian Steinkuhler
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Paola Gallinari
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Antonello Mai
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Maurizio C. Capogrossi
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| | - Carlo Gaetano
- From the Laboratorio di Biologia Vascolare e Terapia Genica (B.I., F.S.), Centro Cardiologico Fondazione “I. Monzino”, IRCCS, Milan; Istituto di Ricerche di Biologia Molecolare I.R.B.M. P. Angeletti (C.D.R., C.S., P.G.), Via Pontina km 30 600, Pomezia, Rome; Laboratorio di Patologia Vascolare (C.C., J.R., G.R., F.M., M.C.C.), Istituto Dermopatico dell’ Immacolata-IRCCS, Rome; Università di Siena (M.P.), Siena; Dipartimento di Cardiochirurgia (P.B.), Centro Cardiologico Fondazione “I. Monzino”,
| |
Collapse
|
199
|
Arany I, Herbert J, Herbert Z, Safirstein RL. Restoration of CREB function ameliorates cisplatin cytotoxicity in renal tubular cells. Am J Physiol Renal Physiol 2007; 294:F577-81. [PMID: 18094030 DOI: 10.1152/ajprenal.00487.2007] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
We have shown that mouse proximal tubule cells (TKPTS) survive H(2)O(2) stress by activating the cAMP-responsive element binding protein (CREB)-mediated transcription via the canonical EGFR-Ras/ERK pathway. By contrast, cisplatin activates EGFR/Ras/ERK signaling in TKPTS cells yet promotes cell death rather than survival. We now demonstrate that the cisplatin-induced activated EGFR/Ras/ERK signaling cascade fails to activate CREB-mediated transcription even in the presence of phosphorylated CREB. CREB-mediated transcription as well as survival was restored by the histone deacetylase (HDAC) inhibitor trichostatine A (TSA), an effective chemotherapeutic agent. Similar to severe oxidant stress, TSA-mediated survival could be abrogated by inhibition of CREB-mediated transcription. These studies confirm the importance of CREB-mediated transcription in the survival of renal cells subjected to either oxidant- or cisplatin-induced stress. The use of cisplatin and TSA in combined chemotherapy protocols may be an effective strategy to enhance cancer cell death and limit nephrotoxicity.
Collapse
Affiliation(s)
- Istvan Arany
- Department of Internal Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA.
| | | | | | | |
Collapse
|
200
|
Abstract
Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted anticancer agents. The first of these new HDACi, vorinostat (suberoylanilide hydroxamic acid), has received Food and Drug Administration approval for treating patients with cutaneous T-cell lymphoma. This review focuses on the activities of the 11 zinc-containing HDACs, their histone and nonhistone protein substrates, and the different pathways by which HDACi induce transformed cell death. A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death.
Collapse
Affiliation(s)
- Milos Dokmanovic
- Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
| | | | | |
Collapse
|